Biotech | 10 March 2026
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
ShunzymeX leverages a proprietary protease to streamline purification
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
